17. August 2017
For the development of this directly compressible excipient no chemical modification was applied. The enhanced functionality enabling a nearly zero order release was achieved by techniques such as physical mixing, high shear mixer granulation and spray drying.
08. March 2017
ABSTRACT: Topiramate (TPM) is effective for multiple seizure types and epilepsy syndromes in children and adults. Topiramate has adverse effects (including cognitive, depression, renal stones), but many of these are low incidence when started at a low dose and slowly titrated to 100 to 200 mg/day. Also, TPM has proven benefit for migraine, obesity, eating disorders, and alcohol use disorders, which can be comorbid in patients with epilepsy and may also be effective in subpopulations within...
18. February 2016
Polyethylene oxide (PEO) has been extensively used as an extended-release excipient in matrix tablets due to its extraordinarily safe, stable, soluble, swellable and erodible properties. The present study aimed to develop once-daily sustained-release tablets using PEO for a highly water-soluble drug, diltiazem hydrochloride (DH), the clinical application of which is limited because of its short half-life in vivo. However, the prophase study demonstrated that the use of PEO alone could only...
28. June 2015
Oxycodone DETERx® is an extended-release (ER), microsphere-in-capsule abuse-deterrent-formulation designed to retain its extended-release properties following tampering or misuse (e.g., chewing, crushing). This study assessed the safety and pharmacokinetics of orally administered intact and crushed Oxycodone DETERx® capsules compared with intact and crushed reformulated OxyContin® tablets and crushed immediate-release oxycodone tablets (IR oxycodone). More